-
公开(公告)号：US11369690B2
公开(公告)日：2022-06-28
申请号：US16111250
申请日：2018-08-24
发明人： Steven R Roffler , Tian-Lu Cheng , Chien-Han Kao , Bing-Mae Chen , Yu-Cheng Su , Hsin-Yi Tung , Kuo-Hsiang Chuang
IPC分类号： C07K16/00 , A61K39/00 , A61K47/68 , A61P35/00 , C07K16/32 , A61K39/395 , C07K16/28 , C07K16/26 , A61K47/14 , A61K47/69 , A61K45/06
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
-
公开(公告)号：US10188742B2
公开(公告)日：2019-01-29
申请号：US15123243
申请日：2015-03-02
发明人： Steven R Roffler , Tian-Lu Cheng , Chien-Han Kao , Bing-Mae Chen , Yu-Cheng Su , Hsin-Yi Tung , Kuo-Hsiang Chuang
IPC分类号： C07K16/00 , A61K39/00 , A61K47/48 , A61K49/00 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/44 , A61K47/68
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
-
公开(公告)号：US20190022245A1
公开(公告)日：2019-01-24
申请号：US16111242
申请日：2018-08-24
发明人： STEVEN R ROFFLER , TIAN-LU CHENG , CHIEN-HAN KAO , BING-MAE CHEN , YU-CHENG SU , HSIN-YI TUNG , Kuo-Hsiang Chuang
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
-
公开(公告)号：US11040111B2
公开(公告)日：2021-06-22
申请号：US16111242
申请日：2018-08-24
发明人： Steven R Roffler , Tian-Lu Cheng , Chien-Han Kao , Bing-Mae Chen , Yu-Cheng Su , Hsin-Yi Tung , Kuo-Hsiang Chuang
IPC分类号： C07K16/00 , A61K47/68 , C07K16/44 , C07K16/32 , C07K16/30 , C07K16/28 , A61K49/00 , A61K47/69 , A61K39/395 , A61K47/60 , A61K39/00
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
-
公开(公告)号：US20210154319A9
公开(公告)日：2021-05-27
申请号：US16111242
申请日：2018-08-24
发明人： STEVEN R ROFFLER , TIAN-LU CHENG , CHIEN-HAN KAO , BING-MAE CHEN , YU-CHENG SU , HSIN-YI TUNG , Kuo-Hsiang Chuang
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
-
公开(公告)号：US20170056523A1
公开(公告)日：2017-03-02
申请号：US15123243
申请日：2015-03-02
发明人： STEVEN R ROFFLER , TIAN-LU CHENG , CHIEN-HAN KAO , BING-MAE CHEN , YU-CHENG SU , HSIN-YI TUNG , Kuo-Hsiang Chuang
CPC分类号： A61K47/6879 , A61K47/6897 , A61K49/0002 , C07K16/2803 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/32 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/622 , C07K2317/624 , C07K2317/73
摘要： Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
摘要翻译： 本文公开了通过靶向癌细胞的肿瘤抗原来特异性地将治疗剂引导至癌细胞的双特异性抗体，从而抑制癌症的生长或阻断癌症的侵袭或转移。 本公开的双特异性抗体包括结合聚乙二醇（PEG）的第一抗原结合位点; 以及结合靶配体例如肿瘤抗原的第二抗原结合位点。
-
7.发明授权公开(公告)号：US09329180B2
公开(公告)日：2016-05-03
申请号：US14057999
申请日：2013-10-18
IPC分类号： G01N33/53 , G01N33/554 , G01N33/68 , G01N33/94 , C07K16/44
CPC分类号： G01N33/554 , C07K16/44 , C07K2317/56 , C07K2319/03 , C12N2503/02 , C12N2510/04 , G01N33/5308 , G01N33/6857 , G01N33/94 , G01N33/9493 , G01N2430/60 , G01N2440/28
摘要： The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
摘要翻译： 本发明提供了一种在细胞膜上提供抗聚乙二醇（PEG）抗体的分离的真核细胞的制备方法。 本发明还提供了通过所述抗-PEG抗体表达细胞定量分析聚乙二醇（PEG）的方法。 本发明预防的基于细胞的定量分析可以灵敏地定量游离的PEG和PEG修饰的大分子（蛋白质，纳米颗粒和脂质体）作为纳克级水平敏感。
-
公开(公告)号：US20210292438A1
公开(公告)日：2021-09-23
申请号：US17340102
申请日：2021-06-07
申请人： ACADEMIA SINICA
发明人： Steve ROFFLER , Tian-Lu Cheng , Yu-Cheng Su , Kuo-Hsiang Chuang
IPC分类号： C07K16/44 , A61K47/60 , A61K47/69 , A61P35/00 , A61K31/55 , A61K31/704 , A61K51/06 , C07K16/28 , C07K16/30 , C07K16/32 , G01N33/574
摘要： A monomeric bispecific polyethylene glycol (PEG) engager that includes an anti-PEG Fab fused to a disulfide stabilized scFv that specifically binds to a cell surface antigen. The PEG engager, in the absence of PEG, remains monomeric upon binding to the cell surface antigen on a cell and remains on the surface of the cell. Also disclosed is a method for treating cancer by administering a PEG engager followed by a PEGylated anti-cancer agent. Further disclosed is a method for diagnosing a cell-mediated disorder by administering a PEG engager followed by a PEGylated diagnostic agent.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.021 秒)
